Expression of endothelin-1 by adrenocortical carcinoma: a new target for anti-cancer therapy?
(2004) Acta Chirurgica Belgica (Bilingual Edition) — Vol. 104, n° 5, p. 581-583 (2004)
Files
10036.pdf
Restricted Access - Adobe PDF
- 4.65 MB
Details
- Authors
- Abstract
- Adrenocortical carcinoma is a rare neoplasm with poor prognosis. Endothelin-1 (ET-1) has been implicated in carcinogenesis, but has never been studied in this neoplasm. A 76-year-old woman with Cushing's syndrome due adrenocortical carcinoma was operated on and the tumour removed was studied by immunohistochemistry for ET-1. Patient history illustrates the poor prognosis of this cancer that became metastatic after one year. Immunohistochemical studies disclosed a strong expression of ET-1 by adrenocortical carcinoma cells. As shown in other cancers, ET-1 expression by adrenocortical carcinoma may suggest a pathogenic role of ET-1 in tumorigenesis that possibly could be countered by ET-1 receptor antagonists. These agents could open new therapeutic perspectives to treat a carcinoma known to have a poor prognosis.
- Affiliations
Citations
Donckier, J., Michel, L., Delos, M., & Havaux, X. (2004). Expression of endothelin-1 by adrenocortical carcinoma: a new target for anti-cancer therapy? Acta Chirurgica Belgica (Bilingual Edition), 104(5), 581-583. https://hdl.handle.net/2078.5/132415 (Original work published 2004)